MedTrace Logo

Role of Atosiban in Recurrent Implantation Failure

NCT04118959 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-09-28

No results posted yet for this study

Summary

ET is the final stage of IVF which independently influences the treatment outcome. Successful embryo implantation is dependent on uterine receptivity. Atosiban is a novel class of drug which is effective in priming the uterus for implantation. It reduces uterine contractions and increases endomyometrial perfusion, both of which have potential benefits regarding improved IRs, CPR, and ongoing pregnancy rates. Atosiban has a good embryonic safety profile. It has no systemic toxicity, no mutagenic effects, and no carcinogenic effects

Conditions

  • Recurrent Implantation Failure

Sponsors & Collaborators

  • Al Baraka Fertility Hospital

    lead OTHER

Eligibility

Min Age
22 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2021-11-20
Completion
2021-11-25

Countries

  • Bahrain

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118959 on ClinicalTrials.gov